منابع مشابه
Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating...
متن کاملanti-cd19 monoclonal antibodies: a new approach to lymphoma therapy
cd19 is expressed on b- lineage cells and follicular dendritic cells and plays a key role in b cell malignancies and autoimmune diseases. thus, it has been considered as potential target for several monoclonal antibodies (mabs). for decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. but, anti- cd19 mabs developed for treating...
متن کاملNew therapy for leukemia, polycythemia, and lymphoma.
X-radiation remains the treatment of choice in most cases of leukemia and lymphoma, but new agents are playing an increasing role in therapy. Radioactive phosphorus does not produce radiation sickness and results with it are comparable to those of x-ray therapy in chronic leukemia. Urethane and nitrogen mustard may produce remissions in patients with chronic leukemia who have become resistant t...
متن کاملNew antibody approaches to lymphoma therapy
The CD20-directed monoclonal antibody rituximab established a new era in lymphoma therapy. Since then other epitopes on the lymphoma surface have been identified as potential targets for monoclonal antibodies (mAb). While most mAbs eliminate lymphoma cells mainly by antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity or direct cell death, others counter mechanisms utiliz...
متن کاملAdvanced Hodgkin Lymphoma: a New Era of Therapy
Therapy of advanced Hodgkin lymphoma (HL) is a rapidly changing field due to a lot of currently emerging data. Treatment approaches are presently based on either the Kairos principle of giving aggressive therapy upfront and considering de-escalation of therapy if the interim PET/CT is negative or the Chronos principle of starting with ABVD followed by escalation of therapy for patients with pos...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2021
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.2020009782